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Snapshot Dx Quiz 
QUESTIONS
1. What is your diagnosis?
a. Systemic sclerosis.
b. Scleromyxedema.
c. Bullous pemphigoid.
d. Sclerodermatous (chronic) graft-versus-host disease.
e. Morphea.
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Questions relate to the image as well as to selected articles in JID, which are listed after 
the questions. Answers will be posted as supplementary material. We hope you enjoy 
this challenge.
2. Which of the following statements is true? 
a. Chronic graft-versus-host disease (GVHD) is an autoimmune syndrome directed toward multiple organs that 
   develops within the first 100 days of transplantation.
b. The skin is the primary organ involved in chronic GVHD.
c. The main pathogenic effectors in chronic GVHD are autoreactive recipient CD4+ T cells that are activated in the 
   presence of costimulatory molecules.
d. Sclerodermatous GVHD is an immune-mediated response that does not involve the dysregulation of tyrosine 
   kinase cascades. 
e. Currently there are a number of medications that successfully treat sclerodermatous GVHD.
3. Which of the following statements is false?
a. Sclerodermatous GVHD is associated with an activation of the EGFR pathway, whose signaling promotes 
   fibrosis through a transforming growth factor-β–dependent mechanism.
b. EGFR inhibition by erlotinib attenuates liver fibrosis and the development of hepatocellular carcinoma.
c. In the sclerodermatous GVHD mouse model used by Morin et al., erlotinib was associated with a reduction 
   in the percentages of effector memory CD4+ T cells in the affected skin.
d. Erlotinib decreased the production of topoisomerase-1 antibodies in sclerodermatous GVHD mice. 
e. Erlotinib limits the production of specific autoantibodies and prevents the production of CD4+ T-memory 
   cells in sclerodermatous GVHD mice but fails to suppress tissue inflammation.
TOPIC ARTICLE
Questions 2 and 3 are based on the following article:
Morin F, Kavian N, Marut W et al. (2015) Inhibition of EGFR tyrosine kinase by erlotinib prevents sclerodermatous graft-versus-host disease in a mouse model. 
J Invest Dermatol 135:2380–8
Answers are available as supplementary material at http://dx.doi.org/10.1038/jid.2015.309.
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